Abimbola Mary Oluwajembola

Abimbola Mary Oluwajembola

Biochemistry, Covenant University, Ota, Nigeria
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2024 in Results in Chemistry
Verified
Journal Article
Open access
AOAbimbola Mary Oluwajembola
Abimbola Mary Oluwajembola
WCWisdom D. Cleanclay
Wisdom D. Cleanclay
AOAbimbola F. Onyia
Abimbola F. Onyia
BCBruno N. Chikere
Bruno N. Chikere
Suleiman ZakariSuleiman Zakari
Suleiman Zakari
OCOpeyemi C. De Campos
Opeyemi C. De Campos

22 October 2024 in Current Research in Pharmacology and Drug Discovery
Verified
Journal Article
Open access
EIEmeka Iweala
Emeka Iweala
DADoris Nnenna Amuji
Doris Nnenna Amuji
AOAbimbola Mary Oluwajembola
Abimbola Mary Oluwajembola
EUEziuche Amadike Ugbogu
Eziuche Amadike Ugbogu
Breast cancer presents a significant challenge due to its heterogeneity and propensity for developing chemoresistance, particularly in the triple-negative subtype. c-Mesenchymal epithelial transition factor (c-Met), a receptor tyrosine kinase, presents a promising target for breast cancer therapy due to its involvement in disease progression and poor prognosis. However, the heterogeneous expression of c-Met within breast cancer subtypes and individual tumors complicates targeted therapy. Also, cancer cells can develop resistance to c-Met inhibitors through various mechanisms, including bypass signaling pathways and genetic mutations. The off-target effects of c-Met inhibitors further limit their clinical utility, necessitating the development of more selective agents. To overcome these challenges, personalized treatment approaches and combination therapies are being explored to improve treatment efficacy while minimizing adverse effects. Novel c-Met inhibitors with improved selectivity and reduced off-target toxicity show promise in preclinical studies. Additionally, targeted delivery systems aim to enhance drug localization and reduce systemic toxicity. Future directions involve refining inhibitor design and integrating c-Met inhibition into personalized treatment regimens guided by molecular profiling. This review explores the mechanisms by which c-Met contributes to chemoresistance in breast cancer and current challenges in targeting c-Met for breast cancer therapy. It discusses strategies to optimize treatment outcomes, ultimately improving patient prognosis and reducing mortality rates associated with this devastating disease.

1 January 2025 in The Scientific World Journal
Verified
Journal Article
Open access
AOAbimbola Mary Oluwajembola
Abimbola Mary Oluwajembola
Suleiman ZakariSuleiman Zakari
Suleiman Zakari
WCWisdom D. Cleanclay
Wisdom D. Cleanclay
TATimothy Ayeni
Timothy Ayeni
AAAdewale Adebosoye
Adewale Adebosoye
Olubanke OgunlanaOlubanke Ogunlana
Olubanke Ogunlana
The unchecked growth and spread of aberrant cells describe a widely diverse collection of disorders that collectively constitute cancer. Conventional therapies for cancer, including radiation therapy, chemotherapy, and surgery, have increased the chances of survival significantly in most patients. These traditional methods usually result in low tumor or tumor cell specificity, significant systemic toxicity, and the development of drug resistance. This review summarizes updates in cancer therapy, some of which include cutting‐edge therapies represented by CAR‐T therapy, targeted therapies, gene therapy, arginine‐depriving therapy, mitochondria‐targeted therapies, neutrophil‐targeted therapies, and the latest PROTAC technology for proteolysis‐targeting chimera. It has emphasized mechanisms underlying these new therapeutic strategies and their translational potential for treating human cancers. We further discuss, for each approach, the challenges, limitations, side effects, and delivery systems. The review proceeds with a dynamic change in the landscape of cancer research in biology, where machine learning and artificial intelligence are increasingly important to improve our understanding of the mechanisms of cancer and treatment responses. We also describe the potential of stem cell therapy, metabolomics, and novel drug delivery systems toward better patient outcomes. The paper pulls together some of the current research findings and results of clinical trials in new therapeutic developments and emerging areas of research that hold out exciting promises for the future progress of cancer treatment.


3 March 2025 in Pharmacological Research - Natural Products
Verified
Journal Article
Closed access
Amina Jega YusufAmina Jega Yusuf
Amina Jega Yusuf
MSMusa Sadiq
Musa Sadiq
ABAisha Iliyasu Bugaje
Aisha Iliyasu Bugaje
MSMustapha Salihu
Mustapha Salihu
AOAbimbola Mary Oluwajembola
Abimbola Mary Oluwajembola
OOOlayinka S. Okoh
Olayinka S. Okoh